HC Wainwright Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX)

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, January 22nd.

Anixa Biosciences Stock Down 3.8 %

Anixa Biosciences stock opened at $3.02 on Tuesday. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $4.20. The firm has a fifty day moving average of $2.70 and a 200-day moving average of $3.05. The firm has a market capitalization of $97.24 million, a P/E ratio of -7.74 and a beta of 0.93.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, research analysts expect that Anixa Biosciences will post -0.46 EPS for the current fiscal year.

Insider Activity at Anixa Biosciences

In related news, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction on Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of Anixa Biosciences stock in a transaction dated Friday, January 17th. The stock was acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the transaction, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 75,289 shares of company stock valued at $177,021. Corporate insiders own 22.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANIX. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new position in Anixa Biosciences during the 3rd quarter valued at about $34,000. Renaissance Technologies LLC grew its stake in shares of Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after purchasing an additional 3,900 shares during the last quarter. Prosperity Wealth Management Inc. acquired a new position in shares of Anixa Biosciences in the 4th quarter worth approximately $54,000. Finally, Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter worth approximately $67,000. 29.13% of the stock is currently owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.